Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Recommendation of “Buy” by Analysts

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) have earned an average recommendation of “Buy” from the eleven research firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, eight have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $22.6667.

Several equities research analysts have recently issued reports on the company. D. Boral Capital reaffirmed a “buy” rating and issued a $19.00 target price on shares of Trevi Therapeutics in a report on Friday, April 17th. JonesTrading dropped their price target on Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a research note on Thursday, March 19th. Morgan Stanley restated an “overweight” rating and set a $20.00 price target on shares of Trevi Therapeutics in a report on Wednesday, May 6th. Stifel Nicolaus set a $30.00 price objective on Trevi Therapeutics in a report on Friday, May 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Trevi Therapeutics in a research report on Monday, April 20th.

Hedge Funds Weigh In On Trevi Therapeutics

Several institutional investors have recently bought and sold shares of TRVI. Pivotal bioVenture Partners Investment Advisor LLC increased its holdings in shares of Trevi Therapeutics by 9.7% in the 3rd quarter. Pivotal bioVenture Partners Investment Advisor LLC now owns 1,256,782 shares of the company’s stock worth $11,500,000 after buying an additional 110,672 shares during the last quarter. Nan Fung Trinity HK Ltd. grew its position in Trevi Therapeutics by 924.2% in the fourth quarter. Nan Fung Trinity HK Ltd. now owns 917,450 shares of the company’s stock worth $11,486,000 after acquiring an additional 827,875 shares in the last quarter. F m Investments LLC purchased a new position in Trevi Therapeutics in the fourth quarter worth about $3,023,000. Pictet Asset Management Holding SA increased its stake in Trevi Therapeutics by 13,507.0% during the fourth quarter. Pictet Asset Management Holding SA now owns 1,532,013 shares of the company’s stock worth $19,181,000 after acquiring an additional 1,520,754 shares during the last quarter. Finally, Comerica Bank increased its stake in Trevi Therapeutics by 19,481.8% during the fourth quarter. Comerica Bank now owns 83,027 shares of the company’s stock worth $1,039,000 after acquiring an additional 82,603 shares during the last quarter. Institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics Stock Performance

TRVI opened at $17.93 on Monday. The stock has a market capitalization of $2.55 billion, a price-to-earnings ratio of -56.03 and a beta of 1.00. The company has a fifty day moving average of $15.06 and a 200 day moving average of $12.95. Trevi Therapeutics has a fifty-two week low of $5.71 and a fifty-two week high of $19.26.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.02). On average, equities research analysts forecast that Trevi Therapeutics will post -0.47 earnings per share for the current year.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.